title: Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.
abstract: BACKGROUND
  Enzyme replacement therapy (ERT) with alpha-galactosidase A (alpha-Gal A) is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease. However, ERT has limitations of a short half-life, requirement for frequent administration, and limited efficacy for patients with renal failure. Therefore, we investigated the efficacy of recombinant adeno-associated virus (rAAV) vector-mediated gene therapy for a Fabry disease mouse model and compared it with that of ERT.
  
  
  METHODS
  A pseudotyped rAAV2/8 vector encoding alpha-Gal A cDNA (rAAV2/8-hAGA) was prepared and injected into 18-week-old male Fabry mice through the tail vein. The alpha-Gal A expression level and globotriaosylceramide (Gb3) levels in the Fabry mice were examined and compared with Fabry mice with ERT. Immunohistochemical and ultrastructural studies were conducted.
  
  
  RESULTS
  Treatment of Fabry mice with rAAV2/8-hAGA resulted in the clearance of accumulated Gb3 in tissues such as liver, spleen, kidney, heart, and brain with concomitant elevation of alpha-Gal A enzyme activity. Enzyme activity was elevated for up to 60 weeks. In addition, expression of the alpha-Gal A protein was identified in the presence of rAAV2/8-hAGA at 6, 12, and 24 weeks after treatment. alpha-Gal A activity was significantly higher in the mice treated with rAAV2/8-hAGA than in Fabry mice that received ERT. Along with higher alpha-Gal A activity in the kidney of the Fabry mice treated with gene therapy, immunohistochemical studies showed more alpha-Gal A expression in the proximal tubules and glomerulus, and less Gb3 deposition in Fabry mice treated with this gene therapy than in mice given ERT. The alpha-gal A gene transfer significantly reduced the accumulation of Gb3 in the tubules and podocytes of the kidney. Electron microscopic analysis of the kidneys of Fabry mice also showed that gene therapy was more effective than ERT.
  
  
  CONCLUSIONS
  The rAAV2/8-hAGA mediated alpha-Gal A gene therapy provided improved efficiency over ERT in the Fabry disease mouse model. Furthermore, rAAV2/8-hAGA-mediated expression showed a greater effect in the kidney than ERT.
authors.affiliation: Department of Biochemistry, School of Medicine, Ewha Womans University, Seoul 158-710, Korea.
authors.forename: Jin-Ok
authors.initials: JO
authors.lastname: Choi
authors.forename: Mi Hee
authors.initials: MH
authors.lastname: Lee
authors.forename: Hae-Young
authors.initials: HY
authors.lastname: Park
authors.forename: Sung-Chul
authors.initials: SC
authors.lastname: Jung
mesh_terms: D000818:Animals; D000229:Dependovirus / Q000235:genetics* / Q000378:metabolism; D056947:Enzyme Replacement Therapy; D000795:Fabry Disease / Q000628:therapy*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D014281:Trihexosylceramides / Q000235:genetics / Q000378:metabolism; D000519:alpha-Galactosidase / Q000235:genetics / Q000378:metabolism
chemical_list: D014281:Trihexosylceramides; C018549:globotriaosylceramide; D000519:alpha-Galactosidase
references.citation: Nat Clin Pract Nephrol. 2008 Jun;4(6):327-36
references.pmid: 18431378
references.citation: Hum Gene Ther. 1999 Jul 1;10(10):1667-82
references.pmid: 10428212
references.citation: Clin Microbiol Rev. 2008 Oct;21(4):583-93
references.pmid: 18854481
references.citation: J Am Soc Nephrol. 2002 Jun;13 Suppl 2:S139-43
references.pmid: 12068026
references.citation: Annu Rev Med. 2006;57:283-96
references.pmid: 16409150
references.citation: Am J Kidney Dis. 2005 Jul;46(1):120-7
references.pmid: 15983965
references.citation: Hum Gene Ther. 1999 Aug 10;10(12):1931-9
references.pmid: 10466627
references.citation: FEBS Lett. 1997 Nov 3;417(1):89-91
references.pmid: 9395081
references.citation: Biochim Biophys Acta. 1998 Apr 28;1406(3):260-6
references.pmid: 9630664
references.citation: Clin Nephrol. 1997 Feb;47(2):71-5
references.pmid: 9049452
references.citation: Mol Ther. 2007 Mar;15(3):492-500
references.pmid: 17191071
references.citation: Mol Ther. 2004 Feb;9(2):231-40
references.pmid: 14759807
references.citation: N Engl J Med. 2001 Jul 5;345(1):9-16
references.pmid: 11439963
references.citation: J Am Soc Nephrol. 2002 Jun;13 Suppl 2:S134-8
references.pmid: 12068025
references.citation: Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2676-81
references.pmid: 11226298
references.citation: J Biol Chem. 1978 Jan 10;253(1):184-90
references.pmid: 201618
references.citation: Glycobiology. 2003 Apr;13(4):305-13
references.pmid: 12626384
references.citation: J Virol. 2000 Oct;74(20):9451-63
references.pmid: 11000214
references.citation: Biologics. 2008 Dec;2(4):823-43
references.pmid: 19707461
references.citation: Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):365-70
references.pmid: 10618424
references.citation: Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2540-4
references.pmid: 9122231
references.citation: Indian J Pathol Microbiol. 1999 Jan;42(1):1-2
references.pmid: 10420677
references.citation: N Engl J Med. 1967 May 25;276(21):1163-7
references.pmid: 6023233
references.citation: Am J Hum Genet. 2001 Jan;68(1):14-25
references.pmid: 11115376
references.citation: Hum Gene Ther. 2009 Aug;20(8):796-806
references.pmid: 19569968
references.citation: Mol Ther. 2006 Jan;13(1):77-87
references.pmid: 16219492
references.citation: J Pediatr. 2004 May;144(5 Suppl):S20-6
references.pmid: 15126980
references.citation: JAMA. 2001 Jun 6;285(21):2743-9
references.pmid: 11386930
references.citation: J Am Soc Nephrol. 2007 May;18(5):1547-57
references.pmid: 17409312
references.citation: J Lipid Res. 1965 Jul;6:428-31
references.pmid: 14336214
references.citation: J Am Soc Nephrol. 2007 Mar;18(3):698-706
references.pmid: 17287429
references.citation: Annu Rev Biochem. 1991;60:257-80
references.pmid: 1883197
references.citation: Ann Neurol. 1992 Apr;31(4):409-15
references.pmid: 1375013
references.citation: J Am Soc Nephrol. 2007 Sep;18(9):2609-17
references.pmid: 17656478
references.citation: Medicine (Baltimore). 2002 Mar;81(2):122-38
references.pmid: 11889412
references.citation: J Virol. 2005 Jan;79(1):214-24
references.pmid: 15596817